Abstract
Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.
Original language | English |
---|---|
Pages (from-to) | 1105-1113 |
Number of pages | 9 |
Journal | Journal of Assisted Reproduction and Genetics |
Volume | 34 |
Issue number | 9 |
DOIs | |
State | Published - 1 Sep 2017 |
Externally published | Yes |
Keywords
- AMH agonist
- AMH analogues
- AMH antagonist
- Anti-Müllerian hormone
- Contraception
- Endometrial cancer
- Fertility preservation
- Fertility treatment
- Menopause
- Müllerian inhibiting substance
- Ovarian cancer
- Ovulation induction
- Polycystic ovarian syndrome